Preferences help
enabled [disable] Abstract
Number of results
2016 | 53 | 3 | 275-308
Article title

An overview of Human Papilloma Virus

Title variants
Languages of publication
Cervical cancer is the second commonest cause of cancer among women. According to the World Health Organization (WHO) data, in 2006 there were 1.4 million women who were suffering from cervical cancer and 80% of deaths among them were of women from developing countries. Genital infection with Human Papilloma Virus (HPV) is one of the major etiological factors for developing cervical cancers in almost all countries (World Health Organization, 2005). Papilloma viruses were first identified, cloned and sequenced from cervical tumor specimens and were subsequently established as important causative agents for the development of cervical cancer. Differences in prevalence rates are observed worldwide. Infection is more common in sexually active young women of 18-30 years and a reduction in acquisition of infection is observed after 30 years. The situation of Cervical cancer in Sri Lanka is identified as the second most common cancer among women in Sri Lanka and approximately 7.74 million women are included in the risk category. It is reported that nearly 850 die from cervical cancer each year.
Physical description
  • Marine Biological Resources Division, National Aquatic Resources and Development Agency (NARA), No15, Crow Island, Colombo 15, Sri Lanka
  • Department of Microbiology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanaka
  • Department of Microbiology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanaka
  • [1] Gerado D Deluca, Jorge basiletti, Joaquinv Gonzalez, Nivolas diaz Vasquez, Rahul H. Lucero, Maria A. picconi (2012). Human Papiloma Virus risk factors for infection and genotype distribution in aboriginal women from Northern Argentina. 72: 461-466.
  • [2] Jorma Isola , Rubel Matrix (2000). Prevalence and determinants of Human papiloma virus infection in Kerala. 1415-1616.
  • [3] Kanishka Karunarathne, Himali Ihalagame, Saman Rohitha, Anco Molijn,Kusuma Gopala, Johanse Skimid, Jin Chen, Sanoj datta ,Sahilesh Meheta (2014). Human Papiloma virus prevalence and types distribution in women with cervical lesion: A cross sectional study in Sri Lanka. 14: 116
  • [4] Rachel L. Winer, Shu-Kuang Lee, James P. Hughes, Diane E. Adam, Nancy B. Kiviat, and Laura A. Koutsky (2002). Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students. 10.1093/aje / kwf180
  • [5] Aggarwal R, Gupta S, Nijhawan R, Suri V, Kaur A, Bhasin V, Arora SK (2002). Prevalence of high - risk human papillomavirus infections in women with benign cervical cytology: A hospital based study from North India. 127: 294-8
  • [6] Nubia Muñoz, M.D, F. Xavier Bosch, M.D, Silvia de Sanjosé, M.D, Rolando Herrero, M.D., Xavier Castellsagué, M.D., Keerti V. Shah, Peter J.F. Snijders (2003). Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. 348: 518-27.
  • [7] Indhu Hariharan, M. Radhakrishna Pillai (2009). Genotypes of the human papillomavirus: Relevance to Indian field trials of the vaccine. 247-260.
  • [8] Stephen Goldstone, Joel M. Palefsky, Anna R. Giuliano, Edson D. Moreira Jr, Carlos Aranda, Heiko Jessen, Richard J. Hillman, Daron G. Ferris, Francois Coutlee, Kai-Li Liaw, J. Brooke Marshall, Xuehong Zhang, Scott Vuocolo,Eliav Barr, Richard M. Haupt, Dalya Guris and Elizabeth, I.O. Garner (2011). Prevalence of and Risk Factors for Human Papillomavirus (HPV) Infection Among HIV-Seronegative Men Who Have Sex With Men: 203.
  • [9] Deepa Gamage, Lalini Rajapaksa, M.R.N. Abeysinghe, Amala de Silva (2012). Prevalence of Human Papilloma Virus Infection and the Burden of Cervical Cancer Attributable to it in the District of Gampaha, Sri Lanka. 978-955-8375-06-8.
  • [10] Glennis M. Andall- Brereto n Felicia Hosein, Rosa A. Salas, Wayne Mohammed, Michele A. Monteil, Vanessa Goleski, Alberto Severini, Sarah M . M . Quesnel,Christin e V. F. Carrington, Laura Lee Boodram, Eldonna Boisson, Patrick E. Akpaka and Rosemarie C. Paul (2011). Human papillomavirus genotypes and their prevalence in a cohort of women in Trinidad. 29(4): 220-6
  • [11] Y.P. Bao, N. LIy, J.S. Smithz, Y..L. Qiao & ACCPAB members (2007). Human papillomavirus type distribution in women from Asia: a meta-analysis. 10.1111/j.1525-1438.2007.00959.x
  • [12] Shirish Shukla, Alok C. Bharti, Sutapa Mahata, Showket Hussain, Rakesh Kumar, Suresh Hedau & Bhudev C. Das (2009). Infection of human papillomaviruses in cancers of different human organ sites. 130, 222-23.
  • [13] Beibei Lu, Ambuj Kumar, Xavier Castellsagué, Anna R Giuliano (2011). Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta Analysis 11:13/1471-2334/11/13.
  • [14] D. Maxwell Parking, Freddie Bray (2006). The burden of HPV related cancers. 24s3 s3/11-s3/25.
  • [15] Chop L Bhusala, Sulochana Manandharb, Meeta Singhc, Aarati Shahd, Sushharma Neupanea, Dibesh Karmacharyab, Kate Cuschierie, Heather Cubiee, Duncan C Gilbertf, Sameer M Dixi (2012). Evidence of HPV subtypes linked with cervical cancer in Nepal. 1(4): 441-445.
  • [16] Rachel L. Winer, Shu-Kuang Lee, James P. Hughes, Diane E. Adam, Nancy B. Kiviat, Laura A. Koutsky (2002). Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students. 10.1093/aje/ kwf 180.
  • [17] Aggarwal R, Gupta S, Nijhawan R, Suri V, Kaur A, Bhasin V, Arora SK (2006). Prevalence of high - risk human papillomavirus infections in women with benign cervical cytology: A hospital based study from North India. Volume 43, Issue 3.
  • [18] Dutra, I. Foroni1, A.R. Couto, M. Lima, J. Bruges-Armas (2012). Human Papillomavirus Worldwide Distribution in Women Without Cervical Cancer. 81: 529-535
  • [19] A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L (2009). Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol 81: 529-535.
  • [20] Czegledy J, Rogo KO, Evander M, Wadell G (1992). High-risk human papillomavirus types in cytologically normal cervical scrapes from Kenya. Med Microbiol Immunol 180: 321-326.
  • [21] Behbakht K, Lynch A, Teal S, Degeest K, Massad S (2004). Social and cultural barriers to Papanicolaou test screening in an urban population. Obstet Gynecol 104: 1355-1361.
  • [22] Boffetta P, Parkin DM (1994). Cancer in developing countries. CA Cancer J Clin 44: 81-90. Cancer IAfRo (2003) Cancer in Africa: epidemiology and prevention. IARC Sci Publ. 1-414.
  • [23] Castellsague X, De Sanjose S, Aguado T (2007). HPV and cervical cancer in the world: 2007 Report (section II countries). Vaccine 25: C27-219.
  • [24] Castellsague X, Klaustermeier J, Carrilho C, Albero G, Sacarlal J, Quint W, Kleter B, Lloveras B, Ismail MR, de Sanjose S, Bosch FX, Alonso P, Menendez C (2008). Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. Int. J Cancer 122: 1901-1904.
  • [25] Castellsague X, Menendez C, Loscertales MP, Kornegay JR, dos Santos F, Gomez-Olive FX, Lloveras B, Abarca N, Vaz N, Barreto A, Bosch FX, Alonso P (2001). Human papillomavirus genotypes in rural Mozambique. Lancet 358: 1429-1430.
  • [26] Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD (2005). A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191: 1808-1816.
  • [27] Centurioni MG, Puppo A, Merlo DF, Pasciucco G, Cusimano ER, Sirito R, Gustavino CA (2005). Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population. BMC Infect Dis 5: 77.
  • [28] Chu KC, Miller BA, Springfield SA (2007). Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status. J Natl Med Assoc 99: 1092-1100, 1102-1094.
  • [29] Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL (2006). Chapter 3: HPV typedistribution in women with and without cervical neoplastic diseases. Vaccine 24.
  • [30] Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S (2005). Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998.
  • [31] Cooper CP, Saraiya M, McLean TA, Hannan J, Liesmann JM, Rose SW, Lawson HW (2005). Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program. J Womens Health (Larchmt) 14: 670-678.
  • [32] Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, Huang RD, Sun LX, Meijer CJ, Qiao YL, Franceschi S (2006). Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer 95: 96-101.
  • [33] Dailard C (2003). HPV in the United States and Developing Nations: A Problem of Public Health or Politics? The Guttmacher Report on Public Policy. 3.
  • [34] Das BC, Hussain S, Nasare V, Bharadwaj M (2008). Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 26: 2669-2679.
  • [35] De Marco F, Houissa-Kchouk F, Khelifa R, Marcante ML (2006). High-risk HPV types in Tunisia. A pilot study reveals an unexpectedly high prevalence of types 58 and 82 and lack of HPV 18 among female prostitutes. J Med Virol 78: 950-953.
  • [36] De Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7: 453-459.
  • [37] De Vuyst H, Parisi MR, Karani A, Mandaliya K, Muchiri L, Vaccarella S, Temmerman M, Franceschi S, Lillo F (2010). The prevalence of human papillomavirus infection in Mombasa, Kenya. Cancer Causes Control 21: 2309-2313.
  • [38] DeMay RM (1996). Cytopathology of false negatives preceding cervical carcinoma. Am J Obstet Gynecol 175: 1110-1113.
  • [39] Dobec M, Bannwart F, Kaeppeli F, Cassinotti P (2009). Automation of the linear array HPV genotyping test and its application for routine typing of human papillomaviruses in cervical specimens of women without cytological abnormalities in Switzerland. J Clin Virol 45: 23-27.
  • [40] Dutra I, Santos MR, Soares M, Couto AR, Bruges-Armas M, Teixeira F, Monjardino L, Hodgson S, Bruges-Armas J (2008). Characterisation of human papillomavirus (HPV) genotypes in the Azorean population, Terceira island. Infect Agent Cancer 3:6.F.D.A. (2010) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59: 626-629.
  • [41] Ferlay J, Parkin DM, Steliarova-Foucher E (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
  • [42] Fukuchi E, Sawaya GF, Chirenje M, Magure T, Tuveson J, Ma Y, Shiboski S, Da Costa M, Palefsky J, Moscicki AB, Makunike-Mutasa R, Chipato T, Smith-McCune KK (2009). Cervical human papillomavirus incidence and persistence in a cohort of HIVnegative women in Zimbabwe. Sex Transm Dis 36: 305-311.
  • [43] Gage JC, Ferreccio C, Gonzales M, Arroyo R, Huivin M, Robles SC (2003). Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detect Prev 27: 466-471.
  • [44] Garland S, Park SN, Ngan HY, Frazer I, Tay EH, Chen CJ, Bhatla N, Pitts M, Shin HR, Konno R, Smith J, Pagliusi S, Park JS (2008). The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGIN conference. Vaccine 26: 5435-5440.
  • [45] Ghim SJ, Basu PS, Jenson A (2002). Cervical Cancer: Etiology, Pathogenesis, Treatment, and Future Vaccines. Asian Pac J Cancer Prev 3: 207-214.
  • [46] Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Martorelli V, Quaglino D (1999). The immune system in the elderly: II. Specific cellular immunity. Immunol Res 20: 109-115.
  • [47] Giorgi Rossi P, Chini F, Bisanzi S, Burroni E, Carillo G, Lattanzi A, Angeloni C, Scalisi A, Macis R, Pini MT, Capparucci P, Guasticchi G, Carozzi FM (2011). Distribution of high and low risk HPV types by cytological status: a population based study from Italy. Infect Agent Cancer 6: 2.
  • [48] Grahovac M, Racic I, Hadzisejdic I, Doric A, Grahovac B (2007). Prevalence of human papillomavirus among Croatian women attending regular gynecological visit. Coll Antropol 31 Suppl 2:73-77.
  • [49] Hammouda D, Clifford GM, Pallardy S, Ayyach G, Chekiri A, Boudrich A, Snijders PJ, van Kemenade FJ, Meijer CJ, Bouhadef A, Zitouni Z, Habib D, Ikezaren N, Franceschi S (2011). Human papillomavirus infection in a population-based sample of women in Algiers, Algeria. Int J Cancer 128: 2224-2229.
  • [50] Hassen E, Chaieb A, Letaief M, Khairi H, Zakhama A, Remadi S, Chouchane L (2003). Cervical human papillomavirus infection in Tunisian women. Infection 31: 143-148.
  • [51] Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M (2000). Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92: 464-474.
  • [52] Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, Snijders PJ (2010). Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in populationbased cervical screening. J Clin Microbiol 48: 797-801.
  • [53] Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, Anton J, Nichols T, Soldan K, Kitchener H (2010). Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 103: 209-216.
  • [54] Kaplan-Myrth N, Dollin J (2007). Cervical cancer awareness and HPV prevention in Canada. Can Fam Physician 53: 693-696, 697.
  • [55] Keam SJ, Harper DM (2008). Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]: profile report. BioDrugs 22: 205-208.
  • [56] Keegan H, Ryan F, Malkin A, Griffin M, Lambkin H (2007). Human papillomavirus prevalence and genotypes in an opportunistically screened Irish female population. Br J Biomed Sci 64: 18-22.
  • [57] Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, van Kemenade FJ, Snijders PJ, Meijer CJ, Franceschi S (2009). HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 101: 202-208.
  • [58] Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A, Peto J (2006). HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95: 56-61.
  • [59] Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T (2008). Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 123: 18641870.
  • [60] Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomers JM, Meijer CJ (1997). Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 6: 799-805.
  • [61] Klug SJ, Hukelmann M, Hollwitz B, Duzenli N, Schopp B, Petry KU, Iftner T (2007). Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 79: 616-625.
  • [62] Konno R, Shin HR, Kim YT, Song YS, Sasagawa T, Inoue M, Park JS (2008). Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine 26 Suppl 12: M30-42.
  • [63] Kornya L, Cseh I, Deak J, Bak M, Fulop V (2002). The diagnostics and prevalence of genital human papillomavirus (HPV) infection in Hungary. Eur J Obstet Gynecol Reprod Biol 100: 231-236.
  • [64] Kulmala SM, Shabalova IP, Petrovitchev N, Syrjanen KJ, Gyllensten UB, Syrjanen SM (2007). Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. J Med Virol 79: 771-781.
  • [65] Lazcano-Ponce E, Alonso P, Ruiz-Moreno JA, Hernandez-Avila M (2003). Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development. Salud Publica Mex 45 Suppl 3: S449-462.
  • [66] Lazcano-Ponce EC, Castro R, Allen B, Najera P, Alonso de Ruiz PA, Hernandez-Avila M (1999). Barriers to early detection of cervical-uterine cancer in Mexico. J Womens Health 8: 399-408.
  • [67] Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Qiao YL, Franceschi S (2006). Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer 95: 1593-1597.
  • [68] Lindemann MLM, Calvo JMS, Antonio JC, Sanz I, Diaz E, Rubio MD, Morena ML (2010). Prevalence and distribution of high-risk genotypes of women with severe cervical lesions in Madrid, Spain: importance of detecting genotype 16 and other high-risk genotypes. Advances in Preventive Medicine 2011.
  • [69] Manhart LE, Holmes KK, Koutsky LA, Wood TR, Kenney DL, Feng Q, Kiviat NB (2006). Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 33: 502-508.
  • [70] Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56: 1-24.
  • [71] Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jeronimo J, Lazcano-Ponce E (2008). Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 26 Suppl 11: L37-48.
  • [72] Ogedegbe G, Cassells AN, Robinson CM, DuHamel K, Tobin JN, Sox CH, Dietrich AJ (2005). Perceptions of barriers and facilitators of cancer early detection among low-income minority women in community health centers. J Natl Med Assoc 97: 162-170.
  • [73] Ogilvie G, Anderson M, Marra F, McNeil S, Pielak K, Dawar M, McIvor M, Ehlen T, Dobson S, Money D, Patrick DM, Naus M (2010). A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med 7: e1000270.
  • [74] Okolo C, Franceschi S, Adewole I, Thomas JO, Follen M, Snijders PJ, Meijer CJ, Clifford GM (2010). Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infect Agent Cancer 5: 24.
  • [75] Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, Ochi H, Nakao S, Someya K, Yamada N, Hamada H, Yoshikawa H (2009). Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 100: 1312-1316.
  • [76] Parkin DM (2002). Cancer incidence in five continents. Volume VIII. IARC Sci Publ 1-781.
  • [77] Parkin DM (2006). The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
  • [78] Popov AA (1991). Family planning and induced abortion in the USSR: basic health and demographic characteristics. Stud Fam Plann 22: 368-377.
  • [79] Public health Row (2007). A glance at HPV in Waterloo Region.
  • [80] Raab SS, Jones BA, Souers R, Tworek JA (2008). The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance. Arch Pathol Lab Med 132: 16-22.
  • [81] Revzina NV, Diclemente RJ (2005). Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS 16: 528-537.
  • [82] Roteli-Martins CM, de Carvalho NS, Naud P, Teixeira J, Borba P, Derchain S, Tyring S, Gall S, Diaz A, Blatter M, Shier RM, Romanowski B, Quint WG, Issam J, Galindo C, Schuind A, Dubin G (2011). Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional study. Int J Gynecol Pathol 30: 173-184.
  • [83] Sahebali S, Depuydt CE, Segers K, Vereecken AJ, Bogers JJ (2003). Cervical cytological screening and human papillomavirus DNA testing in Flanders. Acta Clin Belg 58: 211-219.
  • [84] Sun ZR, Ji YH, Zhou WQ, Zhang SL, Jiang WG, Ruan Q (2010). Characteristics of HPV prevalence among women in Liaoning province, China. Int J Gynaecol Obstet 109: 105-109.
  • [85] Swarz TF (2007). Human papillomavirus -16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer. Expert Rev Obstet Gynecol 2: 1320-1323.
  • [86] Szostek S, Klimek M, Zawilinska B, Kosz-Vnenchak M (2008) Genotype-specific human papillomavirus detection in cervical smears. Acta Biochim Pol 55:687-692.
  • [87] Tarkowski TA, Koumans EH, Sawyer M, Pierce A, Black CM, Papp JR, Markowitz L, Unger ER (2004). Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 189:46-50.
  • [88] Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Munoz N, Snijders PJ, Meijer CJ, Franceschi S (2004). Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 90: 638-645
  • [89] Trope A, Sjoborg K, Eskild A, Cuschieri K, Eriksen T, Thoresen S, Steinbakk M, Laurak V, Jonassen CM, Westerhagen U, Jacobsen MB, Lie AK (2009). Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J Clin Microbiol 47: 2458-2464.
  • [90] Trottier H, Franco EL (2006). The epidemiology of genital human papillomavirus infection. Vaccine 24: 1-15.
  • [91] Tsiodras S, Georgoulakis J, Chranioti A, Voulgaris Z, Psyrri A, Tsivilika A, Panayiotides J, Karakitsos P (2010). Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. BMC Cancer 10: 53.
  • [92] Tworek JA, Jones BA, Raab S, Clary KM, Walsh MK (2007). The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions. Arch Pathol Lab Med 131:1525-1531.
  • [93] Vaucel E, Coste-Burel M, Laboisse C, Dahlab A, Lopes P (2010). Human papillomavirus genotype distribution in cervical samples collected in routine clinical practice at the Nantes University Hospital, France. Arch Gynecol Obstet. WHO/ICO ICoHaCC-HIC (2007a) Human Papillomavirus and Related Cancers in Africa. Summary Report 2010.
  • [94] WHO/ICO ICoHaCC-HIC (2010). Human Papillomavirus and Related Cancers in United States of America. Summary Report 2010.
  • [95] WHO/ICO ICoHaCC (2007b). HPV and cervical cancer in the 2007 report. Vaccine 25 Suppl 3: C1-230.
  • [96] Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA (2003). Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157: 218-226.
  • [97] Womack SD, Chirenje ZM, Blumenthal PD, Gaffikin L, McGrath JA, Chipato T, Ngwalle E, Shah KV (2000). Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. BJOG 107: 33-38.
  • [98] P, Critchlow CW, Hawes SE, Dembele B, Sow PS, Kiviat NB (2003). Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 103: 803-809.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.